Citations

Clear

33 citation(s) found for "Toft, D O".

Minireview: The Intersection of Steroid Receptors with Molecular Chaperones: Observations and Questions
Smith, David F. , Toft, David O.

Mayo Clinic

Molecular Endocrinology | May 4, 2008 | Volume: 22 | Issue: 10 | Pages: 2229-2240

10.1210/me.2008-0089 | PMID 18451092 Get It

Analysis of Hsp90 Cochaperone Interactions Reveals a Novel Mechanism for TPR Protein Recognition
Chadli, Ahmed , Bruinsma, Elizabeth S. , Stensgard, Bridget, Toft, David O.

Mayo Clinic

Biochemistry | January 23, 2008 | Volume: 47 | Issue: 9 | Pages: 2850-2857

10.1021/bi7023332 | PMID 18211007 Get It

Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism
McCollum, Andrea K., TenEyck, Cynthia J., Sauer, Brian M. , Toft, David O., Erlichman, Charles

Mayo Clinic

Cancer Research | November 16, 2006 | Volume: 66 | Issue: 22 | Pages: 10967-10975

10.1158/0008-5472.can-06-1629 | PMID 17108135 Get It

Abstract 17-Allylamino-demethoxygeldanamycin (17-AAG), currently in phase I and II clinical trials as an anticancer agent, binds to the ATP pocket of heat shock protein (Hsp90). This binding induces a cellular stress response that up-regulates many proteins including Hsp27, a member of the small heat shock protein family that has cytoprotective roles, including chaperoning of cellular proteins, regulation of apoptotic signaling, and modulation of oxidative stress. Therefore, we hypothesized that Hsp27 expression may affect cancer cell sensitivity to 17-AAG. In colony-forming assays, overexpression of Hsp27 increased cell resistance to 17-AAG whereas down-regulation of Hsp27 by siRNA increased sensitivity. Because Hsp27 is known to modulate levels of glutathione (GSH), we examined cellular levels of GSH and found that it was decreased in cells transfected with Hsp27 siRNA when compared with control siRNA. Treatment with buthionine sulfoximine, an inhibitor of GSH synthesis, also sensitized cells to 17-AAG. Conversely, treatment of Hsp27 siRNA–transfected cells with N-acetylcysteine, an antioxidant and GSH precursor, reversed their sensitivity to 17-AAG. A cell line selected for stable resistance to geldanamycin relative to parent cells showed increased Hsp27 expression. When these geldanamycin- and 17-AAG-resistant cells were transfected with Hsp27 siRNA, 17-AAG resistance was dramatically diminished. Our results suggest that Hsp27 up-regulation has a significant role in 17-AAG resistance, which may be mediated in part through GSH regulation. Clinical modulation of GSH may therefore enhance the efficacy of Hsp90-directed therapy. (Cancer Res 2006; 66(22): 10967-75)
A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer
Nowakowski, Grzegorz S. , McCollum, Andrea K., Ames, Matthew M. , Mandrekar, Sumithra J. , Adjei, Alex A. , Toft, David O., Safgren, Stephanie L. , Erlichman, Charles , Reid, Joel M. , Safgren, Stephanie L

Mayo Clinic

Clinical Cancer Research | October 24, 2006 | Volume: 12 | Issue: 20 | Pages: 6087-6093

10.1158/1078-0432.ccr-06-1015 | PMID 17062684 Get It

Abstract Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of 17-allylamino-demethoxy-geldanamycin (17-AAG) administered on days 1, 4, 8, and 11 every 21 days and to examine the effect of 17-AAG on the levels of chaperone and client proteins. Experimental Design: A phase I dose escalating trial in patients with advanced solid tumors was done. Toxicity and tumor responses were evaluated by standard criteria. Pharmacokinetics were done and level of target proteins was measured at various points during cycle one. Results: Thirteen patients were enrolled in the study. MTD was defined as 220 mg/m2. Dose-limiting toxicities were as follows: dehydration, diarrhea, hyperglycemia, and liver toxicity. At the MTD, the mean clearance of 17-AAG was 18.7 L/h/m2. There was a significant decrease in integrin-linked kinase at 6 hours after infusion on day 1 but not at 25 hours in peripheral blood mononuclear cells. Treatment with 17-AAG on day 1 significantly increased pretreatment levels of heat shock protein (HSP) 70 on day 4, which is consistent with the induction of a stress response. In vitro induction of a stress response and up-regulation of HSP70 resulted in an increased resistance to HSP90-targeted therapy in A549 cells. Conclusions: The MTD of 17-AAG on a twice-weekly schedule was 220 mg/m2. Treatment at this dose level resulted in significant changes of target proteins and also resulted in a prolonged increase in HSP70. This raises the possibility that HSP70 induction as part of the stress response may contribute to resistance to 17-AAG.
GCUNC-45 Is a Novel Regulator for the Progesterone Receptor/hsp90 Chaperoning Pathway
Chadli, Ahmed , Abel, M. Greg, Jackson, Twila A., Gordon, David F. , Wood, William M., Felts, Sara J. , Horwitz, Kathryn B. , Toft, David O., Graham, J. Dinny

Mayo Clinic

Molecular and Cellular Biology | February 14, 2006 | Volume: 26 | Issue: 5 | Pages: 1722-1730

10.1128/mcb.26.5.1722-1730.2006 | PMID 16478993 Get It

Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
Toft, Mathias , Pielsticker, Liza K., Ross, Owen A. , Aasly, Jan , Farrer, Matthew J. , Ross, Owen A , Toft, Mathias

Mayo Clinic

Neurology | February 13, 2006 | Volume: 66 | Issue: 3 | Pages: 415-417

10.1212/01.wnl.0000196492.80676.7c | PMID 16476943 Get It

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Toft, David O., Ames, Matthew M. , Stensgard, Bridget, Safgren, Stephanie L. , Adjei, Araba A., Sloan, Jeff A. , Atherton, Pamela J. , Vasile, Vlad C. , Salazaar, Sandra, Adjei, Alex A. , Croghan, Gary A., Erlichman, Charles , Goetz, Matthew P. , Reid, Joel M. , Safgren, Stephanie L

Mayo Clinic

Journal of Clinical Oncology | February 18, 2005 | Volume: 23 | Issue: 6 | Pages: 1078-1087

10.1200/jco.2005.09.119 | PMID 15718306 Get It

Purpose We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle in advanced solid tumor patients. We also characterized the pharmacokinetics of 17-AAG, its effect on chaperone and client proteins, and whether cytochrome P450 (CYP) 3A5 and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity. Patients and Methods An accelerated titration design was used. Biomarkers were measured in peripheral-blood mononuclear cells (PBMCs) at baseline and on days 1 and 15, and pharmacokinetic analysis was performed on day 1 of cycle 1. CYP3A5*3 and NQO1*2 genotypes were determined and correlated with pharmacokinetics and toxicity. Results Twenty-one patients received 52 courses at 11 dose levels. DLTs at 431 mg/m2 were grade 3 bilirubin (n = 1), AST (n = 1), anemia (n = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1). No tumor responses were seen. 17-AAG consistently increased heat shock protein (Hsp) 70 levels in PBMCs. At the MTD, the clearance and half-life (t1/2) of 17-AAG were 11.6 L/h/m2 and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t1/2 of 7.63 hours. The CYP3A5*3 and NQO1*2 polymorphisms were not associated with 17-AAG toxicity. The CYP3A5*3 polymorphism was associated with higher 17-AAG clearance. Conclusion The MTD of weekly 17-AAG is 308 mg/m2. 17-AAG induced Hsp70 in PBMCs, indicating that Hsp90 has been affected. Further evaluation of 17-AAG is ongoing using a twice-weekly regimen, and this schedule of 17-AAG is being tested in combination with chemotherapy.
Thiopurine S‐Methyltransferase (TPMT) Pharmacogenetics: Role of Chaperone Proteins in variant Allozyme Degradation
Wang, L., Sullivan, William J. , Toft, D O, Weinshilboum, Richard

Mayo Clinic

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90460-7 Get It

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
Requirement of Heat Shock Protein 90 for Human Hepatitis B Virus Reverse Transcriptase Function
Flores, Dafna, Toft, David O., Wang, Xingtai, Nguyen, David H. , Hu, Jianming

Mayo Clinic

Journal of Virology | November 12, 2004 | Volume: 78 | Issue: 23 | Pages: 13122-13131

10.1128/jvi.78.23.13122-13131.2004 | PMID 15542664 Get It

ABSTRACT The initiation of reverse transcription and nucleocapsid assembly in hepatitis B virus (HBV) depends on the specific recognition of an RNA signal (the packaging signal, ε) on the pregenomic RNA (pgRNA) by the viral reverse transcriptase (RT). RT-ε interaction in the duck hepatitis B virus (DHBV) was recently shown to require the molecular chaperone complex, the heat shock protein 90 (Hsp90). However, the requirement for RT-ε interaction in the human HBV has remained unknown due to the inability to obtain a purified RT protein active in specific ε binding. We now report that Hsp90 is also required for HBV RT-ε interaction. Inhibition of Hsp90 led to diminished HBV pgRNA packaging into nucleocapsids in cells, which depends on RT-ε interaction. Furthermore, using truncated HBV RT proteins purified from bacteria and five purified Hsp90 chaperone factors, we have developed an in vitro RT-ε binding assay. Our results demonstrate that Hsp90, in a dynamic process that was dependent on ATP hydrolysis, facilitated RT-ε interaction in HBV, as in DHBV. Specific ε binding required sequences from both the amino-terminal terminal protein and the carboxy-terminal RT domain. Only the cognate HBV ε, but not the DHBV ε, could bind the HBV RT proteins. Furthermore, the internal bulge, but not the apical loop, of ε was required for RT binding. The establishment of a defined in vitro reconstitution system has now paved the way for future biochemical and structural studies to elucidate the mechanisms of RT-ε interaction and chaperone activation.
Loss of proliferative potential during terminal differentiation coincides with the decreased abundance of a subset of heterogeneous ribonuclear proteins.
Minoo, Parviz , Sullivan, W. Patrick, Solomon, Luc, Martin, Terence E., Toft, D O, Scott, R E

Mayo Clinic

The Journal of cell biology | May 15, 2004 | Volume: 109 | Issue: 5 | Pages: 1937-1946

10.1083/jcb.109.5.1937 | PMID 2808514 Get It

The decrease in abundance of a subset of highly conserved basic nuclear proteins is established to correlate with the loss of proliferative potential in association with the process of terminal differentiation in murine mesenchymal stem cells and human keratinocytes. These proteins, designated P2Ps for proliferation potential proteins, have apparent molecular masses of 30-40 kD, are associated with the 30-40S substructures of nuclear hnRNP complexes, and are recognized by antibodies made against core proteins of hnRNP particles. They also share an epitope in common with heat shock protein-90 (hsp90) and are recognized by two mAbs against hsp90. Two-dimensional electrophoretic Western blots furthermore show that P2Ps make up a subset of hnRNP proteins. Cells that possess these proteins express the potential to proliferate whether or not they are traversing the cell cycle. These include rapidly growing cells, reversibly growth-arrested cells, and nonterminally differentiated cells. In contrast, cells that have irreversibly lost their proliferative potential, such as terminally differentiated cells, show a marked reduction in the abundance of P2Ps as determined by immunodetection on Western blots. A correlation, therefore, exists between the presence of this subset of nuclear proteins and the proliferative potential in two cell types. These results raise the possibility that as a subset of hnRNP proteins, P2Ps may mediate posttranscriptional control of the processing of specific RNAs required for cell proliferation.